Search

Displaying results 5261 - 5270 of 9670 in total
  1. Drug

    Human Menstrual Blood-derived Stem Cells

    go.drugbank.com/drugs/DB15738
    Investigational

    MenSCs are special compared to older methods of adult stem cell extraction such as bone marrow stem cell extraction because MenSC extraction is a non-invasive method. … Because this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind.

  2. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    It is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc.

  3. Drug

    Amredobresib

    go.drugbank.com/drugs/DB21566
    Investigational

    Amredobresib has a monoisotopic molecular weight of 467.25 Da. … The usage of the INN stem '-bresib' in the name indicates that Amredobresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.

  4. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  5. Drug

    Clofutriben

    go.drugbank.com/drugs/DB21636
    Investigational

    Clofutriben has a monoisotopic molecular weight of 424.09 Da. … Clofutriben is under investigation in clinical trial NCT05307328 (SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome).

  6. Drug

    Sulfapyridine

    go.drugbank.com/drugs/DB00891
    ApprovedWithdrawn

    Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.

  7. Drug

    Alprenolol

    go.drugbank.com/drugs/DB00866
    ApprovedWithdrawn

    One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.

  8. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The development of PW2101 has since been discontinued. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  9. Drug

    WX-UK1

    go.drugbank.com/drugs/DB05476
    Investigational

    Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas.

  10. Drug

    Telcagepant

    go.drugbank.com/drugs/DB12228
    Investigational

    Telcagepant has been investigated for the treatment of Migraine. … It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine.